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To the Editor,
We thank Drs. Sookaromdee and Wiwanitkit for their interest and contribution to our article. There is a growing evidence of renal 
dysfunction in patients with thalassemia. Although the process is multifactorial (the disease itself with regular transfusion, iron 
accumulation in the parenchyma and toxicity of chelators), oxidative stress seems to be the main mechanism of renal damage. 
Several studies have shown the beneficial effects of antioxidants (curcumin, glutamine) in prevention of chemotherapy-induced 
nephrotoxicity by decreasing oxidative damage. Considering the significantly increased life expectancy of thalassemia patients with 
long-term complications, we think the role and effects of antioxidant treatments in routine follow-up of the thalassemia patients 
should be investigated in prospective studies. 
Best Regards
Zeynep Karakaş, Serap Karaman
Reply to the Authors:
To the Editor,
The combined use of plerixafor and granulocyte-colony 
stimulating factor (G-CSF) improves mobilization in poor 
mobilizers. However, there are limited data available on the use 
of plerixafor in healthy donors [1,2]. The effects of influenza A 
infection on stem cell mobilization are not known. 
A 46-year-old male was selected as an HLA-matched donor for 
a patient diagnosed with acute myeloid leukemia (AML). Donor 
assessment was performed in accordance with the standard 
operating procedure prepared for JACIE (SOP: BMT-CU-006, 
Donor Assessment and Safety). The donor was given 10 mg/kg/
day G-CSF. He developed a dry persistent cough, chills, fever 
of 39 °C, fatigue, and flu-like symptoms on day 3 of G-CSF 
administration. The donor was considered to have an upper 
respiratory tract infection, which could not be attributed to 
only G-CSF administration. The family members of the donor 
were found to have similar symptoms. Thus, blood and urine 
cultures were obtained and he was started on levofloxacin in 
addition to paracetamol; G-CSF was continued. A respiratory 
tract virus panel was performed on a nasal smear using a PCR-
based technique. The peripheral blood leukocyte count was 
22,000/µL but CD34+ cells represented just 0.07% of all cells 
(11/µL) on day 5 of G-CSF administration; this was considered 
to reflect “poor mobilization”. Therefore, 0.24 mg/kg plerixafor 
was administered “just in time,” in addition to G-CSF, on night 
5, after the donor had been given all necessary information and 
informed consent had been obtained. Two hours after the 11th 
dose of G-CSF, the leukocyte count was 45,000/µL, of which 
0.33% (148/µL) were CD34+ cells. Peripheral stem cell apheresis 
was performed using the Donor Spectra Optia Apheresis System 
(Terumo BCT, Lakewood, CO, USA). A total of 15.20x108 nuclear 
cells/kg were collected. The product contained 3.92x106 CD34+ 
cells/kg, 14.91x107 CD3+ cells/kg, 17.36x107 CD19+ cells/kg, 
and 7.17x107 CD56+ cells/kg. G-CSF was discontinued after an 
adequate number of stem cells had been collected, but the fever 
persisted. Oseltamivir at 150 mg twice daily was then prescribed 
for the donor because the respiratory tract virus panel 
examination revealed influenza A infection. The fever became 
controlled 24 h after oseltamivir administration. The plerixafor 
procedure was considered to have permitted “sufficient 
mobilization” in a healthy donor who could not be mobilized 
with G-CSF probably because of his influenza infection.
Many factors including age, sex, body mass index, baseline 
leukocyte count, and comorbid conditions may compromise 
mobilization [3]. Although certain viral infections may cause 
poor mobilization, data on the influence of influenza in this 
context are rather limited [4]. Cytokine production or cytokine 
storm developing during influenza infection may be presumed 
to impair stem cell mobilization [5]. A combination of G-CSF and 
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plerixafor can be used to treat mobilization failure and is usually 
well tolerated [6,7]. The only option upon stem cell mobilization 
failure with G-CSF is bone marrow harvesting. Our donor was 
given plerixafor “just in time”; he had an active infection and 
did not consent to bone marrow harvesting. While plerixafor is 
usually used for mobilization in lymphoma or myeloma patients, 
literature data are available about its use in allogeneic settings 
[8]. Stem cells in numbers adequate for safe transplantation 
were collected in a single procedure. 
This report indicates that influenza A may suppress the 
hematopoietic system, negatively affecting stem cell 
mobilization. The problem may be overcome by plerixafor 
administration.
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To the Editor, 
We read the publication entitled “Use of Plerixafor to Mobilize 
a Healthy Donor Infected with Influenza A” and found it to 
be very interesting [1]. Yeral et al. [1] mentioned that “The 
effects of influenza A infection on stem cell mobilization are 
not known” and concluded that “This report indicates that 
influenza A may suppress the hematopoietic system, negatively 
affecting stem cell mobilization. The problem may be overcome 
by plerixafor administration” [1]. This article may provide a 
new observation and confirm the usefulness of plerixafor in 
achieving stem cell mobilization. Nevertheless, it should be 
noted that this is not the first case of stem cell transplantation 
in which the donor has influenza A infection. Lee et al. [2] 
reported stem cell transplantation from a related donor infected 
with influenza H1N1 2009 and in that case the transplantation 
was completely done without noting any problem of stem cell 
mobilization due to the influenza virus. Regardless of using 
plerixafor, however, stem cell transplantation in cases in which 
the donor has influenza infection is a considerable challenge 
and it is questionable whether the procedure should be done 
then or not.
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